Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab

Blood

Volumn 114, Issue 14, 2009, Pages 3052-3055

  Ambrose, Lyn R ^a   Morel, Anne Sophie ^a   Warrens, Anthony N ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD52 ANTIGEN; MESSENGER RNA;

ANTIGEN EXPRESSION; ARTICLE; CELL SURFACE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MONITORING; EOSINOPHIL; FLOW CYTOMETRY; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA; LYMPHOCYTE; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; EOSINOPHILS; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; NEUTROPHILS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 70449483876     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-203075     Document Type: Article

References (25)

1. Keating M, Coutre S, Rai K, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma. 2004;4(4):220-227. (Pubitemid 38528876)
2. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy. 2001;3(3):137-143. (Pubitemid 33039652)
3. Demko S, Summers J, Keegan P, et al. FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist. 2008;13(2):167-174. (Pubitemid 351342581)
4. Dearden CE. Role of antibody therapy in lymphoid malignancies. Br Med Bull. 2007;83:275-290. (Pubitemid 47616189)
5. Isaacs JD, Watts RA, Hazleman BL, et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet. 1992;340(8822):748-752.
6. Lockwood CM, Thiru S, Isaacs JD, et al. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet. 1993; 341(8861):1620-1622. (Pubitemid 23175246)
7. Isaacs JD, Hazleman BL, Chakravarty K, et al. Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. J Rheumatol. 1996;23(6):1103-1106. (Pubitemid 26196106)
8. Verstovsek S, Tefferi A, Kantarjian HM, et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009;15(1):368-373.
9. Slavin S, Waldmann H, Or R, et al. Prevention of graft versus host disease in allogeneic bone marrow transplantation for leukemia by T cell depletion in vitro prior to transplantation. Transplant Proc. 1985;17:465-467. (Pubitemid 15170744)
10. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents GvHD following non-myeloablative stem-cell transplantation. Cytotherapy. 2001;3(3):197-201. (Pubitemid 33039657)
11. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery. 2004;136(4):754-760. (Pubitemid 39311300)
12. Tryphonopoulos P, Madariaga JR, Kato T, et al. The impact of Campath 1H induction in adult liver allotransplantation. Transplant Proc. 2005;37(2):1203-1204. (Pubitemid 40590836)
13. Thai NL, Khan A, Tom K, et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: one- and two-year outcomes. Transplantation. 2006;82(12):1621-1624. (Pubitemid 46035639)
14. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25(35):5616-5623.
15. Lin TS, Flinn IW, Lucas MS, et al. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia. 2005;19(7):1207-1210. (Pubitemid 40946005)
16. Elsner J, Hochstetter R, Spiekermann K, et al. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood. 1996;88(12):4684-4693. (Pubitemid 26419153)
17. Hale G. CD52 (Campath-1). J Biol Regul Homeost Agents. 2001;15:386-391.
18. Rebello P, Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods. 2002;260:285-302. (Pubitemid 34132893)
19. Riechmann L, Clark M, Waldmann H, et al. Reshaping human antibodies for therapy. Nature. 1988;332(6162):323-327.
20. Genzyme. Campath Prescribing Information. http://www.campath.com. 2008. Accessed June 2009.
21. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood. 1993;82(3):807-812. (Pubitemid 23221659)
22. Frame JN, Sheedy D, Cartagena T, et al. Optimal conditions for in vitro T cell depletion of human bone marrow by Campath-1a plus complement as demonstrated by limiting dilution analysis. Bone Marrow Transplant. 1989;4(1):55-61. (Pubitemid 19064907)
23. Hertenstein B, Wagner B, Bunjes D, et al. Emergence of CD52-, phosphatidylinositolglycananchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood. 1995;86(4):1487-1492.
24. Wendtner C-M, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission: experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004;18:1093-1101. (Pubitemid 38786968)
25. Tan HP, Kaczorowski DJ, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant. 2006;6:2409-2417. (Pubitemid 44359428)